<DOC>
	<DOCNO>NCT00004139</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial compare effectiveness gemcitabine plus either docetaxel irinotecan treating patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Gemcitabine Plus Docetaxel Irinotecan Treating Patients With Stage IIIB Stage IV Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare complete overall response rate gemcitabine docetaxel versus gemcitabine irinotecan chemotherapy naive patient stage IIIB IV non-small cell lung cancer . II . Compare overall failure free survival , duration response , toxicity associate combination regimens patient population . OUTLINE : This randomize study . Patients stratify accord disease stage ( stage IIIB v stage IV without CNS involvement v stage IV CNS involvement v recurrent/progressive disease post surgery and/or radiotherapy ) . Patients randomize one two treatment arm . Arm I : Patients receive gemcitabine IV 30 minute immediately follow irinotecan IV 90 minute day 1 8 . Arm II : Patients receive gemcitabine IV 30 minute immediately follow docetaxel IV 60 minute day 1 8 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Patients achieve partial complete response stable disease receive treatment least 6 course 2 additional course beyond maximum response , investigator 's discretion . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter disease progression death . PROJECTED ACCRUAL : A total 72 patient ( 36 per treatment arm ) accrue study within 12 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IIIB , IV , recurrent nonsmall cell lung cancer ( NSCLC ) include : Squamous cell carcinoma Adenocarcinoma ( include bronchoalveolar cell ) Large cell anaplastic carcinoma ( include giant clear cell carcinoma ) Stage IIIB eligible CALGB protocol consist combined chemotherapy chest radiotherapy permit Malignant pleural effusion allow CNS metastasis allow follow completion cranial radiotherapy Unidimensionally bidimensionally measurable disease Solid tumor mass hilar lesion surround aerated lung Pleural base mass Mediastinal hilar adenopathy clearly measurable No bone disease No pleural pericardial effusion No irradiated lesion unless progression document follow radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2 time upper limit normal ( ULN ) Alkaline phosphatase less 2.5 time ULN SGOT great 1.5 time ULN Renal : Creatinine great 2.0 mg/dL Other : No malignancy within past 5 year except curatively treat basal squamous cell skin cancer carcinoma situ cervix breast Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior chemotherapy NSCLC Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy At least 2 week since prior whole brain radiotherapy stereotactic radiotherapy CNS disease Surgery : At least 2 week since prior surgery CNS disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>